ISPOR Europe panel report: Pricing and reimbursement of multiple indication medicines: Can a balance be found between different stakeholder perspectives to optimise value and access for patients, while ensuring sustainable and affordable innovation?
March 2025
This ISPOR Europe 2024 panel report explores pricing and reimbursement (P&R) of multiple medicines in Europe. Work has culminated from the panellists and audience of ~800 participants, where they discussed key challenges and forward-looking solutions for multi-indication products. The insights are captured in full within the report.
Panel
- Amanda Cole (University College London)
- Claudio Jommi (Universita del Piemonte Orientale)
- Julien Patris (argenx)
Moderator
- Jens Grueger (Boston Consulting Group)
